The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-16. Anything still debated is marked as such rather than presented as settled.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
== Society and culture == The scalp plays an important role in the aesthetics of the face. Androgenic alopecia, or male pattern hair loss, is a common cause of concern to men. It may be treated with varying rates success by medication (e.g. finasteride, minoxidil) or hair transplantation. If the scalp is heavy and loose, a common change with ageing, the forehead may be low, heavy and deeply lined. The brow lift procedure aims to address these concerns. Scalping is the act of removing a human scalp, usually with hair, as a trophy. Often associated with the history of North America, scalping developed independently on multiple continents and dates back to antiquity.
=== Biochemical synthesis === Glycocyamine is formed in the mammalian organism primarily in the kidneys by transferring the guanidine group of L-arginine by the enzyme L-Arg:Gly-amidinotransferase (AGAT) to the amino acid glycine. From L-arginine, ornithine is thus produced, which is metabolized in the urea cycle by carbamoylation to citrulline.
Deadlift – 400 kg (882 lb) (2005 Pojedynek Gigantów) Keg drop Deadlift – 295–350 kg (650–771 lb) x 6 lifts in 33.89 seconds (2005 World's Strongest Man) Keg drop Squat – 265–340 kg (584–750 lb) x 7 reps in 21.28 seconds (2007 World's Strongest Man - Group 4) Keg drop Squat – 260–360 kg (573–794 lb) x 7 reps in 27.53 seconds (2005 World's Strongest Man) (former world record) Log lift – 172 kg (379 lb) (2005 Met-Rx Grand Prix) Log lift (for reps) – 130 kg (287 lb) x 14 reps (2006 Moscow Grand Prix) Axle press (for reps) – 140 kg (309 lb) x 11 reps (2006 WSMC Poland) (World Record) Apollon wheel press – 166 kg (366 lb) x 4 reps (2004 Arnold Strongman Classic) Viking press – 150 kg (331 lb) x 12 reps (2007 Mohegan Sun Grand Prix) Kettlebell press – 80 kg (176 lb) x 8 reps (2009 Globe's Strongest Man) Atlas Stones – 5 stones weighing 115–155 kg (254–342 lb) on tall platforms in 21.09 seconds (2006 Strongman Super Series Moscow Grand Prix) (World Record) Ding carry – 160 kg (353 lb) for 90 metres (2005 World's Strongest Man) (World Record) Asia Stone / shield carry – 175 kg (386 lb) for 127.4 metres (2002 World's Strongest Man) (World Record) Africa Stone carry – 175 kg (386 lb) for 110 metres (2000 World's Strongest Man - Group 5) (World Record) Block carry – 180 kg (397 lb) for 80 metre course in 41.32 seconds (2002 Europe's Strongest Man) (World Record) Fridge carry (super yoke) – 410 kg (904 lb) for 20 metres in 15.29 seconds (2005 World's Strongest Man) Timber carry – 392 kg (864 lb) (40' ramp) in 22.93 seconds (Raw grip) (2006 Arnold Strongman Classic) Wheelbarrow carry (no straps) – 300 kg (661 lb) (25m course) in 15.50 seconds (2003 IFSA Finland Grand Prix) (World Record) Farmer's walk (no straps) – 150 kg (331 lb) per each hand for 60m course in 19.90 seconds (2006 Strongman Super Series Poland Grand Prix) (World Record) Farmer's walk (no straps) – 137.5 kg (303 lb) per each hand for 70m course in 22.48 seconds (2003 Strongman Super Series Finland Grand Prix) (World Record) Super Yoke – 360 kg (794 lb) for 20 meters in 7.66 seconds (2006 World Strongman Cup Federation, Poland) (World Record) Medicine Ball Toss – 23 kg (51 lb) for 4.88 meters (2004 Arnold Strongman Classic) Power Stairs – (225 kg (496 lb) total of 14 steps) – 40.94 seconds (2008 World's Strongest Man) (World Record) Power Stairs – (230 kg (507 lb) total of 23 shallow steps) – 26.33 seconds (2006 World's Strongest Man) (World Record) Power Stairs – (200 kg (441 lb), 230 kg (507 lb) & 250 kg (551 lb) total of 15 high steps) – 31.22 seconds (2004 Europe's Strongest Man) (World Record) Power Stairs – (225 kg (496 lb), 250 kg (551 lb) & 275 kg (606 lb) total of 15 steps) – 28.56 seconds (2005 Nautilus Grand Prix) (World Record) Tyre Flip – 380 kg (838 lb) Tyre x 8 flips - 20.81 seconds (2004 Holland Champions Trophy) and 400 kg (882 lb) Tyre x 8 flips - 22.87 seconds (2006 Moscow Grand Prix) (former world records) Flip & drag – 400 kg (882 lb) tyre x 4 flips and 300 kg (661 lb) anchor & chain drag for 30 meters – 39.01 seconds (2002 World's Strongest Man) (world record) Conan's wheel (Basque circle) – 360 kg (794 lb) 765° rotation (2006 World Strongman Cup Russia) (World Record) Conan's wheel (Basque circle) – 317.5 kg (700 lb) 1,203° rotation (2003 Strongman Super Series Holland Grand Prix) (World Record) Conan's wheel (Basque circle) – 300 kg (661 lb) 1,440° rotation (2002 World's Strongest Man - Group 5) (former world record) Train pull – 16,000 kg (35,274 lb) for 25 meter course in 30.78 seconds (2003 World's Strongest Man) (World Record) Truck pull – 24,000 kg (52,911 lb) for 20 meter course in 26.05 seconds (2003 IFSA Strongman World Record Breakers) (World Record) Plane pull – 40,000 kg (88,185 lb) for 25 meter course in 36.67 seconds (2008 World's Strongest Man) (World Record) During training: (Self-claims)
Penile measurements vary, with studies that rely on self-measurement reporting a significantly higher average size than those which rely on measurements taken by health professionals. A 2015 systematic review of 15,521 men in which the subjects were measured by health professionals showed that the average length of an erect human penis is 13.12 cm (5.17 inches) long, while the average circumference of an erect human penis is 11.66 cm (4.59 inches). Among all primates, the human penis is the largest in girth, but is comparable to the chimpanzee penis and the penises of certain other primates in length. Penis size is affected by genetics, but also by environmental factors such as fertility medications and chemical/pollution exposure.
== Clinical significance == There are many diseases where failure to adequately absorb iron contributes to iron deficiency and iron deficiency anemia. The treatment will depend on the hepcidin levels that are present, as oral treatment will be unlikely to be effective if hepcidin is blocking enteral absorption; in these cases, parenteral iron treatment would be appropriate. Studies have found that measuring hepcidin would help establish the optimal treatment for a patient, but as this is not widely available, C-reactive protein (CRP) is used as a surrogate marker. Chronic alcohol consumption can lead to excess iron accumulation in the liver, which may contribute to the development of alcoholic liver disease. Chronic alcohol use may increase iron accumulation by inhibiting hepcidin gene expression. The main mechanisms appear to be increasing oxidative stress through its metabolite acetaldehyde, and by inhibiting the release of interleukin 6 (IL-6) from macrophages; each of these actions reduce the expression and DNA-binding activity of the transcription factor C/EBPα, which would otherwise stimulate hepcidin expression. Beta thalassemia, one of the most common congenital anemias, arises from partial or complete failure to synthesize beta-globin, a component of hemoglobin. Excessive iron absorption is one of the main features of beta thalassemia and can lead to severe morbidity and mortality.
Sources: en.wikipedia.org
=== Physical properties === In its pure form, molybdenum is a silvery-grey metal with a Mohs hardness of 5.5 and a standard atomic weight of 95.95 g/mol. It has a melting point of 2,623 °C (4,753 °F), sixth highest of the naturally occurring elements; only tantalum, osmium, rhenium, tungsten, and carbon have higher melting points. It has one of the lowest coefficients of thermal expansion among commercially used metals.
== Clinical significance == Mutations in the 38 human genes for the cytoplasmic and mitochondrial enzymes have been associated with a wide range of illnesses, with 56+ different diseases given OMIM codes. The majority of reported diseases (46/56) were autosomal recessive. Nearly every reported aminoacyl-tRNA synthetase gene has been associated with at least one disease caused by mutations (with the notable exception of TARS3). Mutations in the mitochondrial enzyme have been associated with a number of genetic disorders including Leigh syndrome, West syndrome and CAGSSS (cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss and skeletal dysplasia syndrome).
=== Antibody heterogeneity === Product heterogeneity is common in monoclonal antibodies and other recombinant biological products and is typically introduced either upstream during expression or downstream during manufacturing. These variants are typically aggregates, deamidation products, glycosylation variants, oxidized amino acid side chains, as well as amino and carboxyl terminal amino acid additions. These seemingly minute structural changes can affect preclinical stability and process optimization as well as therapeutic product potency, bioavailability and immunogenicity. The generally accepted purification method of process streams for monoclonal antibodies includes capture of the product target with protein A, elution, acidification to inactivate potential mammalian viruses, followed by ion chromatography, first with anion beads and then with cation beads. Displacement chromatography has been used to identify and characterize these often unseen variants in quantities that are suitable for subsequent preclinical evaluation regimens such as animal pharmacokinetic studies. Knowledge gained during the preclinical development phase is critical for enhanced product quality understanding and provides a basis for risk management and increased regulatory flexibility. The recent Food and Drug Administration's Quality by Design initiative attempts to provide guidance on development and to facilitate design of products and processes that maximizes efficacy and safety profile while enhancing product manufacturability.
Thymulin (also known as thymic factor or its old name facteur thymique serique) is a nonapeptide produced by two distinct epithelial populations in the thymus first described by Bach in 1977. It requires zinc for biological activity. Its peptide sequence is H-Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn-OH. The hormone is believed to be involved in T-cell differentiation and enhancement of T and NK cell actions. Besides this rather paracrine or auto-organic effects on the thymus dependent immune system, thymulin seems to have neuroendocrine effects as well. There exist bidirectional interactions between thymic epithelium and the hypothalamus-pituitary axis (for example, thymulin follows a circadian rhythm and physiologically elevated ACTH levels correlate positively with thymulin plasma levels and vice versa). A recent focus has been on the role of thymulin as an effector on proinflammatory mediators/cytokines. A peptide analog of thymulin (PAT) has been found to have analgesic effects in higher concentrations and particularly neuroprotective anti-inflammatory effects in the CNS. Astrocytes seem to be the target for thymulin for this effect. Researchers hope to develop drugs thwarting inflammatory processes associated with neurodegenerative diseases and even rheumatism with the help of thymulin analogs. Significantly decreased thymulin levels have been associated with anorexia nervosa.
In the European Union, the Food Supplements Directive requires that only those supplements that have been proven safe can be sold without a prescription. For most vitamins, pharmacopoeial standards have been established. In Nigeria, the National Agency for Food and Drug Administration and Control has issued regulations which govern the supply and contents of vitamins and supplements. In England, the National Health Service makes free vitamins available for babies and children under 4 through its "Healthy Start" programme, adopted due to concerns that young children, even if feeding well, would not receive an adequate intake of vitamins A and D.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.